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Pretreatment of human neutrophils with granulocyte macrophage-colony stimulating factor (GM-CSF) augments everal biological responses to 
chemoattractants (e.g. the respiratory burst, degranulation, and chemotaxis). However, little is known regarding the intracellular effects of priming 
with GM-CSF. In the present study, we have investigated the effects of GM-CSF on the generation of diacylglycerol (DAG), a proposed mediator 
of neutrophil responses. GM-CSF alone produced only a small increase in cellular DAG mass, which was most apparent after 30 min. GM-CSF 
pretreatment (60 min), however, caused a striking augmentation i  DAG generation in response to the chemoattractant formyl-methionyl-leucyl- 
phenylalanine (fMLP), compared with neutrophils preincubated without GM-CSF. The augmentation i  DAG generation correlated with an en- 
hancement by GM-CSF of superoxide generation in response to fMLP. The data suggest hat GM-CSF may exert some of its biological effects 
by enhancing DAG generation in response to a second agonist. 
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1. INTRODUCTION 
The neutrophil is the major phagocytic cell involved 
in the first line of defense against invading micro- 
organisms. Recent studies have identified a family of 
proteins which stimulate the differentiation and pro- 
liferation of stem cells to form mature blood cells [ 1,2]. 
One of these, GM-CSF, stimulates the proliferation and 
differentiation of neutrophilic granulocytes and macro- 
phages. GM-CSF also has a variety of effects on the 
function of mature cells. In neutrophils, these include 
an enhancement of the superoxide-generating 
respiratory burst induced by agonists such as fMLP 
[3,4]. However, the priming of the superoxide genera- 
tion is slow, requiring l-2 h of preincubation with GM- 
CSF. Additional metabolic effects of GM-CSF have 
been noted, including enhanced synthesis of platelet ac- 
tivating factor in response to chemoattractants [5]. 
GM-CSF may also function invivo to enhance neutro- 
phi1 responses; Baldwin et al. [6] reported that injected 
GM-CSF enhances the frequently depressed neutrophil 
functions in patients with AIDS. 
Little is known about the signal transduction path- 
ways involved in GM-CSF-primed neutrophil activa- 
tion. GM-CSF alone does not stimulate the generation 
or release of superoxide, arachidonate, or inositol phos- 
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phates. G-proteins have recently been implicated in the 
early effects of GM-CSF in neutrophils which include 
pH changes, Na+ influx, and gene expression [7,8]. Di- 
acylglycerol has recently been implicated as a mediator 
of a variety of fMLP-activated neutrophil responses, 
including superoxide generation and degranulation 
[9,10]. In the present studies, we have tested the effect 
of GM-CSF on superoxide generation and diglyceride 
generation, the latter using a method which quantifies 
mass. GM-CSF produces only a small increase in basal 
DAG levels, but markedly enhances DAG generation in 
response to fMLP. Enhancement of DAG generation 
correlates with priming of fMLP-activated superoxide 
generation. 
2. MATERIALS AND METHODS 
2.1. Materials 
Hespan (6.2% hetastarch in 0.9070 NaCI) was obtained from 
American Hospital Supply Corp. Lymphocyte Separation Medium 
(6.2% Ficoll, 9.4% sodium diatrizoate) was purchased from Bionetics 
Laboratory Products. Octyl-@-D-glucopyranoside, adenosine-5 ‘-tri- 
phosphate, fMLP, DL-dithiothreitol and fetal bovine serum were 
from Sigma. Recombinant human GM-CSF (200000 units/ml 
(5 #g/ml)) was purchased from AMGen biologicals. [Y-~~P]ATP 
(spec. act. 4000 Ci/mmol) was purchased from ICN Radiochemicals. 
Cardiolipin (bovine heart) was shipped on dry-ice from Avanti polar 
lipids. E. coli diglyceride kinase was obtained from Lipidex. Silica gel 
60 F254 TLC plates were from EM Science. All other reagents and 
solvents were of the highest quality available commercially. 
2.2. Isolation of neutrophils 
Human neutrophils were isolated from the peripheral blood of 
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healthy donors as described previously [ll]. Isolated cells were 
suspended in PBS buffer which contained 5% fetal bovine serum and 
were used within 4 h [9,12]. 
Cells (1 x IO’ in 0.8 ml) were preincubated at 37°C for the in- 
dicated time either with or without GM-CSF in 13 x 100 mm poly- 
styrene tubes, and were then stimulated with fMLP (1 /IM). At ap- 
propriate times, incubations were terminated by transfer to 
13 x 100 mm glass test tubes (with Teflon screw caps) containing 3 ml 
of chloroform/methanol (1: 2, v/v). Lipids were extracted by the 
method of Bligh and Dyer [13]. Diacylglycerol was quantified by con- 
version to [32P]phosphatidic acid using the method of Preiss et al. 
1141, with some modifications as described in [9]. Lipids were ex- 
tracted, and [32P]phosphatidic acid was separated by TLC and 
visualized by autoradiography. Phosphatidie acid~ontaining areas 
were scraped and counted as detailed previously [9,15]. 
3. RESULTS AND DISCUSSION 
Weisbart and colleagues [4] previously showed that 
preincubation of neutrophils with GM-CSF augments 
superoxide generation in response to fMLP. We initial- 
ly confirmed the priming effect of GM-CSF on super- 
oxide generation. Neutrophils preincubated for 3 min 
and then stimulated with fMLP showed a respiratory 
burst rate of 4.6 nmol/min per IO6 cells (table 1). After 
prolonged preincubation (30 and 60 min) at 37’C, 
fMLP-stimulated superoxide generation had declined 
slightly to about 2.5 nmol/min per lo6 cells (table 1). In 
contrast, cells preincubated with 100 pM GM-CSF for 
either 30 or 60 min (but not 3 min) showed a 3-4-fold 
increase in respiratory burst rate compared with 
similarly preincubated controls (table 1). Longer prein- 
cubation did not result in a further enhancement of 
superoxide generation under these conditions (data not 
shown). Neutrophils primed with higher concentration 
of GM-CSF (200 PM) did not show any appreciable in- 
crease in respiratory burst rate (table 1). Neutrophils in- 
cubated with GM-CSF alone for up to 120 min did not 
produce any superoxide (data not shown). Thus, GM- 
Table 1 
Effect of purified recombinant GM-CSF-priming on neutrophils 
respiratory burst 
Incubation mixture Time Stimulus nmol superoxide/min 
(min) per lo6 cells 
Cells + diluent 03 fMLP 4.6 F 0.4 
Cells + diluent 30 fMLP 2.5 f 0.4 
Cells + diluent 60 fMLP 2.6 rt 0.3 
Cells + GM-CSF (100 PM) 03 fMLP 4.5 f 0.3 
Cells + GM-CSF (100 PM) 30 fMLP 8.4 f 0.5 
Cells + GM-CSF (100 PM) 60 fMLP 9.8 f 0.6 
Cells + GM-CSF (200 PM) 60 fMLP 10.4 + 1.1 
Superoxide generation was measured by monitoring cytochrome c 
reduction using an SLM/AmincoDW2000 spectrophotometer in the 
dual wavelength mode (As49 minus A540) with constant slow stirring 
(Teflon-coated stir-bar) as described in 1211. Values are means f SE 
of 3 observations using a single cell preparation. The experiment was 
repeated 3 times using 3 separate cell preparations 
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Fig. 1. Time course for the production of diacylglycerol in GM-CSF 
(100 PM) treated (open squares) and untreated human neutrophils 
(filled squares). Cells were incubated at 37’C. Aliquots (10’ cells/data 
point) were removed, and analyzed for DAG. For each time point, the 
mean f SE of 3 incubations from same cell preparation are shown 
(DAG pmol/107 cells). Results are representative of two experiments 
using separate cell preparations. 
CSF primes human neutrophils for an enhanced fMLP- 
stimulated respiratory burst. 
We previously studied the generation of diacyl- 
glycerol in response to fMLP in neutrophils which had 
been primed with phorbol lZmyristate, 13-acetate, an 
activator of protein kinase C [9]. In those studies, prim- 
ing with PMA resulted in increased DAG generation in 
response to fMLP, and the enhanced DAG generation 
correlated with the enhanced functional response. 
Herein, we have investigated the effects of GM-CSF on 
neutrophil DAG levels. We find that GM-CSF alone 
has only a small effect on basal levels of DAG, par- 
ticularly at time points beyond 30 min (fig.1, open 
squares). In the absence of GM-CSF, basal DAG re- 
mained unchanged. Thus, GM-CSF produces a small 
increase above basal DAG levels, and this change may 
account for some of the early functional/biochemical 
changes seen with GM-CSF alone (e.g. GM-CSF is a 
weak secretagogue [ 161, and induces changes in 
sodium/proton antiport activity [8]), 
The effect of GM-CSF pretreatment on DAG genera- 
tion in response to a second stimulus was evaluated. 
Neutrophils primed with GM-CSF for 60 min and then 
stimulated with fMLP showed a rapid (60 s) and sus- 
tained (beyond 5 min) increase in diglyceride levels 
(fig.2, open squares). The amount of DAG generated 
was considerably larger than that produced in response 
to fMLP alone (filled squares) following preincubation 
for the same period without GM-CSF. Thus, priming 
with GM-CSF enhances the production of DAG in re- 
sponse to fMLP, and the enhanced DAG generation 
correlates with the augmentation of fMLP-activated 
superoxide generation. 
The mechanism by which GM-CSF primes fMLP- 
activated DAG generation is uncertain, but is similar in 
some respects to priming by other agents. For example, 
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Fig.2. Time course for fMLP (1 PM)-stimulated DAG generation in 
cells preincubated for 60 min at 37°C with 100 pM GM-CSF (open 
squares) or parallel preincubated control cells (filled squares). Ali- 
quots (IO’ cells/data point) were removed, and analyzed for DAG. 
For each time point, the mean zt SE of 3 incubations from same cell 
preparation are shown. Results are representative of two experiments 
using separate cell preparations. 
a low dose of PMA which does not itself activate the 
respiratory burst, primes the burst towards a second 
stimulus such as fMLP [ 171. We have shown that PMA 
priming is accompanied by augmented DAG generation 
in response to fMLP [9]. While low-dose PMA primes 
for responses to fMLP, it does not enhance superoxide 
generation when a second, high dose, of PMA is used. 
Similarly, GM-CSF fails to prime for an enhanced ox- 
idative response to PMA [3]. Although the mechanism 
for neutrophil priming by GM-CSF is unknown, it is 
possible that the small enhancement of DAG generation 
at later times is acting via protein kinase C, similar to 
low doses of PMA [9]. The overall effect may relate to 
increased chemoattractant receptor number and/or 
receptor coupling to the phospholipase(s) which 
generate DAG. For example, low doses of PMA have 
been shown to mobilize an intracellular store of fMLP 
receptors, causing increased expression of fMLP recep- 
tors on the cell surface of human neutrophils [l&19]. 
Similarly, Weisbart et al. [2OJ showed that GM-CSF 
augments the number of GM-CSF receptors on the cell 
surface. Thus, although the time course is longer, prim- 
ing by GM-CSF shows a number of similarities to prim- 
ing by phorbol esters. In summary, the present studies 
show that GM-CSF causes a weak enhancement of 
basal DAG levels which occurs slowly (> 30 min), and 
that it causes a significant enhancement of DAG 
generation in response to a chemoattractant. 
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